CD34+-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-centre experience
- 1 November 1997
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 20 (10) , 827-834
- https://doi.org/10.1038/sj.bmt.1700981
Abstract
Between July 1994 and December 1996, PBSC were mobilized in 28 patients with poor-risk hematological malignancies and solid tumors. CD34+ cells were positively immunoselected using the Ceprate CS System. By December 1996, 22 patients had been reinfused with a median of 3.325 (0.078–9.5) × 106/kg CD34+ cells. In three patients unselected back-up PBSC had to be transfused along with selected CD34+ cells because of a CD34+ cell number 1.0 × 109/l and a median day number of 56 (range, 10–180) until platelets >20.0 × 109/l (ie platelet transfusion independence). Time to leukocyte and platelet recovery was significantly shorter in patients receiving >2.0 × 106/kg purified CD34+ cells as compared to patients reinfused with 2.0 × 106/kg CD34+ cells and a significantly delayed platelet recovery time in patients receiving 6/kg purified CD34+ cells. There was a trend for a better overall survival and a lower probability of progression/relapse as compared to the historical controls. We observed five episodes of serious opportunistic infections (three pulmonary fungal infections, two cases of cryptosporidiosis) after the take. Four of these patients had been reinfused with 6/kg CD34+ cells probably indicating a delayed immune reconstitution after CD34+-selected PBSCT.Keywords
This publication has 0 references indexed in Scilit: